News | Business
24 Oct 2017 11:47
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • News
  • Sport
  • Weather
  • Olympic Games
  • Ski Report
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Business

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.

    21 March 2017

    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Business News
     24 Oct: Fletcher's trading halt ahead of AGM
     24 Oct: Vocus puts Orcon up for sale
     24 Oct: Kiwi near five-month low
     23 Oct: Vocus aims to sell NZ business by June
     20 Oct: Shares rise as weak dollar helps companies
     20 Oct: Right to reject media merger, court hears
     20 Oct: Auckland Airport spend under microscope
     Top Stories

    RUGBY RUGBY
    Duffie, Tamanivalu keep Savea on the outer More...


    BUSINESS BUSINESS
    Fletcher's trading halt ahead of AGM More...



     Today's News

    Entertainment:
    Peter Dinklage has become a dad for the second time 11:34

    Living & Travel:
    French President Emmanuel Macron's dog Nemo interrupts meeting to pee on fireplace 11:17

    International:
    James Toback: Who is the latest Hollywood mogul accused of sexual harassment? 11:17

    Law and Order:
    Thames attempted murder accused in court 11:07

    Entertainment:
    Liam Payne has praised his girlfriend Cheryl Tweedy as a “fantastic” mum 11:04

    Law and Order:
    Murder-accused to face Hamilton jury 10:47

    Entertainment:
    Kit Harington “cried” when he read the final ‘Game of Thrones’ script 10:34

    Business:
    Fletcher's trading halt ahead of AGM 10:27

    Business:
    Vocus puts Orcon up for sale 10:07

    Entertainment:
    Jennifer Aniston hopes ‘Friends’ will “inspire people” to put down their phones and communicate with one another 10:04


     News Search






    Power Search


    © 2017 New Zealand City Ltd